HC Wainwright Comments on Asensus Surgical, Inc.’s Q1 2025 Earnings (NYSEAMERICAN:ASXC)

Asensus Surgical, Inc. (NYSEAMERICAN:ASXCFree Report) – Investment analysts at HC Wainwright issued their Q1 2025 earnings per share estimates for Asensus Surgical in a research note issued on Friday, March 22nd. HC Wainwright analyst S. Ramakanth anticipates that the company will earn ($0.03) per share for the quarter. HC Wainwright has a “Buy” rating and a $2.00 price target on the stock. The consensus estimate for Asensus Surgical’s current full-year earnings is ($0.19) per share. HC Wainwright also issued estimates for Asensus Surgical’s Q2 2025 earnings at ($0.03) EPS, Q3 2025 earnings at ($0.03) EPS, Q4 2025 earnings at ($0.03) EPS and FY2028 earnings at $0.14 EPS.

Asensus Surgical Stock Down 14.3 %

ASXC stock opened at $0.24 on Monday. Asensus Surgical has a 12-month low of $0.20 and a 12-month high of $0.86. The stock has a market cap of $63.46 million, a price-to-earnings ratio of -0.75 and a beta of 1.46.

Institutional Investors Weigh In On Asensus Surgical

Institutional investors and hedge funds have recently modified their holdings of the stock. JPMorgan Chase & Co. purchased a new stake in shares of Asensus Surgical in the first quarter worth about $31,000. FMR LLC lifted its stake in shares of Asensus Surgical by 444.2% in the first quarter. FMR LLC now owns 48,584 shares of the company’s stock worth $32,000 after acquiring an additional 39,656 shares in the last quarter. Ergoteles LLC acquired a new position in shares of Asensus Surgical in the first quarter worth about $36,000. Two Sigma Investments LP acquired a new position in shares of Asensus Surgical in the first quarter worth about $44,000. Finally, Virtu Financial LLC acquired a new position in shares of Asensus Surgical in the second quarter worth about $30,000. Hedge funds and other institutional investors own 10.06% of the company’s stock.

About Asensus Surgical

(Get Free Report)

Asensus Surgical, Inc, a medical device company, engages in the research, development, and sale of medical device robotics to enhance minimally invasive surgery (MIS) in the United States, Europe, the Middle East, Africa, and Asia. It digitizes the interface between the surgeon and the patient to pioneer a new era of Performance-Guided surgery by unlocking clinical intelligence for surgeons to enable consistently superior outcomes and a new standard of surgery.

See Also

Earnings History and Estimates for Asensus Surgical (NYSEAMERICAN:ASXC)

Receive News & Ratings for Asensus Surgical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Asensus Surgical and related companies with MarketBeat.com's FREE daily email newsletter.